Summary
For Year 2026-27, Eris Lifesciences reports the following shareholding: Total Promoters at 53.92%, Mutual Fund at 18.22%, Insurance at 1.31%, Foreign Institutional Investors at 6.39%, Domestic Institutional Investors at 0.82%, and Retail at 19.33%. This breakdown provides a quick snapshot of ownership distribution for Eris Lifesciences in 2026-27.
Eris Lifesciences FAQs
As of 04-2026, the promoter shareholding in Eris Lifesciences stands at 53.92% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Eris Lifesciences is 6.39% and 0.82% respectively.
The retail shareholding of the Eris Lifesciences is 19.33%.
Changes in shareholding patterns of Eris Lifesciences can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Eris Lifesciences are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Eris Lifesciences Associated Pages
